TPC
JBIO

Takeda Pharmaceutical Company’s Jade Biosciences JBIO Stock Holding History

Takeda Pharmaceutical Company’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-388
Closed -$402K – 14
2024
Q1 		$402K Hold
388
– – 0.14% 13
2023
Q4 		$307K Buy
+388
New +$198K 0.09% 13

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Takeda Pharmaceutical Company's JBIO Position: Q2 2024 in Review

Takeda Pharmaceutical Company sold out of Jade Biosciences (JBIO) in Q2 2024, closing a stake of 388 shares — an estimated $402K sold.

Takeda Pharmaceutical Company first reported a position in JBIO in Q4 2023 and held it in 2 quarters. The position peaked at $402K in Q1 2024. 80 funds tracked by Wall St. Rank hold JBIO as of Q2 2024.

  • Takeda Pharmaceutical Company reported no remaining Jade Biosciences position as of Q2 2024 after selling out during the quarter.
  • Takeda Pharmaceutical Company sold 388 Jade Biosciences shares in Q2 2024, an estimated $402K.
  • Takeda Pharmaceutical Company first reported a position in Jade Biosciences in Q4 2023 and held it in 2 quarters.
  • Takeda Pharmaceutical Company's Jade Biosciences position peaked at $402K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2024.

Based on Takeda Pharmaceutical Company's 13F filing for Q2 2024, filed 13 Feb 2025.